<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511434370</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511434370</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Topical Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Changes at the nodal and perinodal axonal domains: a basis for multiple sclerosis pathology?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Desmazières</surname><given-names>Anne</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Sol-Foulon</surname><given-names>Nathalie</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lubetzki</surname><given-names>Catherine</given-names></name>
</contrib>
<aff id="aff1-1352458511434370">CRICM-UPMC/Inserm UMR_S 975/CNRS UMR 7225, Hôpital de la Salpêtrière, Paris, France</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1352458511434370">Catherine Lubetzki, CRICM, Hôpital de la Salpêtrière, 75013, Paris, France. Email: <email>catherine.lubetzki@upmc.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>2</issue>
<fpage>133</fpage>
<lpage>137</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>6</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>How axonal damage, a major prognostic factor of multiple sclerosis disability progression, is induced, is likely to be multifactorial. Whereas axonal injury has been identified as a consequence of myelin loss, the possibility of an additional direct damage is also suggested. In this context, recent data have highlighted the nodal and perinodal axonal domains of the myelinated neurons as potential targets of the disease process, opening new perspectives in multiple sclerosis pathophysiology.</p>
</abstract>
<kwd-group>
<kwd>autoimmune response</kwd>
<kwd>myelin</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>neurodegeneration</kwd>
<kwd>node of Ranvier</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458511434370" sec-type="intro">
<title>Introduction</title>
<p>Neuronal damage in multiple sclerosis (MS) has attracted much attention during the last 10 years, with several reports suggesting it might occur early in the disease process, and contribute significantly to disease severity. Initially described in the white matter, this neuronal pathology is now well recognized in MS gray matter, and is considered as a major factor of disability progression, notably in the progressive phases. Pathophysiology of neuronal injury in MS is most probably multifactorial. Within white matter lesions, axonal damage is mostly considered a result of chronic demyelination-induced vulnerability. Recent data, however, have challenged this hypothesis by demonstrating, in a mouse experimental inflammatory model, that axonal pathology with focal swelling can be detected in the absence of (or prior to) demyelination.<sup><xref ref-type="bibr" rid="bibr1-1352458511434370">1</xref></sup> Mechanisms of the gray matter neuronal damage are currently unclear, although roles have been discussed for chronic meningeal inflammation, demyelination-induced damage, and neuronal degeneration secondary to axonal loss.<sup><xref ref-type="bibr" rid="bibr2-1352458511434370">2</xref></sup> In addition, whether an immune response directed to neuronal/axonal targets might result in ‘direct’ neuronal damage is still an open question. Many adaptive immune responses to components of the white matter have been identified in MS.<sup><xref ref-type="bibr" rid="bibr3-1352458511434370">3</xref></sup> These are directed against constitutive myelin proteins and lipids. Recent reports, however, have provided examples in MS and/or experimental models of an immune response targeting neuronal antigens<sup><xref ref-type="bibr" rid="bibr4-1352458511434370">4</xref>–<xref ref-type="bibr" rid="bibr6-1352458511434370">6</xref></sup> in particular axoglial antigens expressed at nodal and perinodal domains of myelinated fibers.<sup><xref ref-type="bibr" rid="bibr7-1352458511434370">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458511434370">8</xref></sup> Importantly, these specific domains, which support the propagation of saltatory conduction along myelinated fibers, are profoundly modified after demyelination. Although, experimentally, this immune response elicits neuronal pathology in both white and gray matter,<sup><xref ref-type="bibr" rid="bibr7-1352458511434370">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458511434370">8</xref></sup> whether it is pathogenic in MS still needs definitive proofs. Nevertheless, these reports open new and interesting perspectives into the pathophysiology of neuronal damage in MS.</p>
<p>We will successively review: (i) the molecular organization of the different nodal and perinodal domains of myelinated axons in the central nervous system (CNS), a very active field of research during the last few years; (ii) the changes detected at the nodal and perinodal axonal domains after demyelination and how this might affect axonal function and remyelination; and (iii) the recent data on auto-immunity directed against antigens of the nodal and perinodal axonal domains in MS and experimental models.</p>
</sec>
<sec id="section2-1352458511434370">
<title>Nodal and perinodal organization</title>
<p>Myelinated axons are subdivided into the axonal initial segment (AIS), where action potentials are generated, the myelinated internodes, the nodes of Ranvier and perinodal regions, namely the paranodes and juxtaparanodes (<xref ref-type="fig" rid="fig1-1352458511434370">Figure 1</xref>).</p>
<fig id="fig1-1352458511434370" position="float">
<label>Figure 1.</label>
<caption>
<p>Schematic representation of the molecular organization of the nodal and perinodal regions of a CNS myelinated fiber.</p>
</caption>
<graphic xlink:href="10.1177_1352458511434370-fig1.tif"/></fig>
<p>The nodes of Ranvier are short unmyelinated domains highly enriched in voltage-gated sodium channels (Na<sub>v</sub>), which allow the regeneration and propagation of the action potentials by depolarization of the plasma membrane.<sup><xref ref-type="bibr" rid="bibr9-1352458511434370">9</xref></sup> These channels consist of a pore-forming α-subunit and one or more subtypes of accessory β-subunits.<sup><xref ref-type="bibr" rid="bibr10-1352458511434370">10</xref></sup> In addition to the sodium channels, other proteins cluster at the nodes: the neuronal isoform of neurofascin, Nfasc186, a transmembrane cell adhesion molecule (CAM) from the immunoglobulin superfamily, the GPI-anchored protein contactin, and the scaffold proteins ankyrinG (AnkG) and βIVspectrin which provide a link with the actin cytoskeleton.<sup><xref ref-type="bibr" rid="bibr11-1352458511434370">11</xref>–<xref ref-type="bibr" rid="bibr13-1352458511434370">13</xref></sup> Various extra-cellular matrix proteins (ECM) are also enriched at the nodes, where they could play a role in buffering the nodal environment and in nodal stability.<sup><xref ref-type="bibr" rid="bibr14-1352458511434370">14</xref></sup> Surrounding the nodes are the paranodes, which form during myelination by the tight interaction between the distal, uncompacted loops of myelin and the axolemma. The paranodal septate-like axoglial junctions comprise the axonal adhesion proteins Caspr and contactin, which interact with the glial isoform of neurofascin, Nfasc155. The absence of any of these markers leads to a loss of the axoglial junction.<sup><xref ref-type="bibr" rid="bibr15-1352458511434370">15</xref>,<xref ref-type="bibr" rid="bibr16-1352458511434370">16</xref></sup> The axonal part of the paranodal complex is further stabilized by the interaction of Caspr with the cytoskeletal adapter 4.1B, which binds to ankyrinB (AnkB) and αII/βIIspectrin. The axoglial junctions restrict the diffusion of the nodal complex and segregate it from the juxtaparanodes, the section of the myelinated segments directly adjacent to the paranodes. The main feature of juxtaparanodes is that they contain delayed rectifier voltage-gated potassium channels (K<sub>v</sub>), whose function is still unclear, though they may play a role in protecting developing or injured neurons.<sup><xref ref-type="bibr" rid="bibr12-1352458511434370">12</xref>,<xref ref-type="bibr" rid="bibr17-1352458511434370">17</xref></sup> Caspr2, a transmembrane Caspr-related protein, and the GPI-anchored protein TAG1, which is both expressed in neurons and glial cells, are also clustered at the juxtaparanodes. The neuronal TAG1 binds <italic>trans</italic> homophilically to its glial counterpart and to Caspr2 in <italic>cis</italic>. It has been described that the localization of the juxtaparanodal complex is impaired in their absence, as well as when the link between Caspr2 and the cytoskeleton is altered.<sup><xref ref-type="bibr" rid="bibr18-1352458511434370">18</xref>,<xref ref-type="bibr" rid="bibr19-1352458511434370">19</xref></sup></p>
</sec>
<sec id="section3-1352458511434370">
<title>Modifications of nodal and perinodal organization in multiple sclerosis and related experimental models</title>
<p>The importance of axon–myelin interactions for axonal integrity is highlighted by studies on pathological material taken from patients with MS and experimental models. Dysmyelinating mutants or animals unable to synthesize some of the major myelin constituents present an abnormal distribution of ion channels at the node of Ranvier and/or paranodal and juxtaparanodal alterations, which is associated with axonal swelling and degeneration.<sup><xref ref-type="bibr" rid="bibr20-1352458511434370">20</xref>–<xref ref-type="bibr" rid="bibr24-1352458511434370">24</xref></sup> Moreover, the nodes of Ranvier can be the initial point of axonal swelling prior to demyelination, as shown recently by performing <italic>in vivo</italic> imaging studies in an experimental autoimmune encephalomyelitis (EAE) model.<sup><xref ref-type="bibr" rid="bibr1-1352458511434370">1</xref></sup></p>
<p>On demyelinated axons, an abnormal Na<sub>v</sub> channel distribution has been reported, both in an EAE model<sup><xref ref-type="bibr" rid="bibr25-1352458511434370">25</xref></sup> and in MS lesions,<sup><xref ref-type="bibr" rid="bibr25-1352458511434370">25</xref>,<xref ref-type="bibr" rid="bibr26-1352458511434370">26</xref></sup> with a disappearance of nodal aggregates, replaced by diffuse expression along the denuded portions of the axon. Redistribution of sodium channels along the denuded axon concerns not only the mature Na<sub>v</sub>1.6 isoform, but also the immature Na<sub>v</sub>1.2 isoform, which is mainly expressed prior to myelination and on non-myelinated axons. Although both isoforms can support conduction in demyelinated axons, and can therefore be considered as an adaptive response, the Na<sub>v</sub>1.6 expression might favor axonal damage, by production of persistent current driving the inversion of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger and subsequent calcium-mediated axonal damage. In contrast, the Na<sub>v</sub>1.2 isoform, which does not produce large persistent currents, might favor axonal protection.<sup><xref ref-type="bibr" rid="bibr25-1352458511434370">25</xref></sup> The nodal Nfasc186 profile is also modified after demyelination: an increased spread of Nfasc186 clusters occurs along the axons.<sup><xref ref-type="bibr" rid="bibr27-1352458511434370">27</xref></sup></p>
<p>In addition to the loss of the nodal complex aggregation, paranodal (Caspr) and juxtaparanodal (K<sub>v</sub>1.2, Caspr2) proteins were also found to be redistributed along the denuded axon.<sup><xref ref-type="bibr" rid="bibr26-1352458511434370">26</xref>,<xref ref-type="bibr" rid="bibr28-1352458511434370">28</xref></sup> Interestingly, alterations in paranodal structure might be an early event in MS lesions, as abnormally large aggregates of Nfasc155 and Caspr were detected in the absence of nodes of Ranvier abnormalities and demyelination.<sup><xref ref-type="bibr" rid="bibr27-1352458511434370">27</xref>,<xref ref-type="bibr" rid="bibr28-1352458511434370">28</xref></sup> These changes were detected at axo-glial junctions located at the periphery of demyelinating lesions and on axons expressing dephosphorylated neurofilament, suggesting early axonal damage. This may suggest that the axo-glial junction is an area of particular vulnerability during the initial steps of tissue damage. The extent of paranodal disruption correlates with local microglia inflammation, but not with the density of infiltrating lymphocytes, indicating that activated microglia may provide signals that destabilize axo-glial junctions.<sup><xref ref-type="bibr" rid="bibr29-1352458511434370">29</xref></sup></p>
<p>Axo-glial organization is fully restored after remyelination as observed in shadow plaques in tissue taken from patients with MS. Furthermore, importance of signals initiating node formation for myelination is highlighted by the detection, within partially remyelinated lesions, of Na<sub>v</sub> channel (re)aggregation preceding remyelination. This has suggested that a defect of Na<sub>v</sub> channel aggregation might be involved in the remyelination failure of demyelinated lesions with spared axons and oligodendroglial cells.<sup><xref ref-type="bibr" rid="bibr26-1352458511434370">26</xref></sup></p>
<p>These studies in both experimental models and in MS show that disruption of the axo-glial interactions might be an initial event in the tissue damage process, followed by profound modifications of nodal and perinodal axonal protein distributions. Recent data have also suggested the potential role of these axo-glial antigens as targets in MS immune response.</p>
</sec>
<sec id="section4-1352458511434370">
<title>Autoimmunity against nodal and perinodal antigens in multiple sclerosis and experimental models</title>
<p>Using a proteomic screen on a glycoprotein fraction isolated from human myelin by affinity chromatography, new potential targets of an MS autoimmune response have been identified. A combination of two-dimensional gel electrophoresis, western blotting and mass spectrometry revealed Nfasc155 and TAG1 as targets of humoral immune response in MS<sup><xref ref-type="bibr" rid="bibr7-1352458511434370">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458511434370">8</xref></sup> (<xref ref-type="fig" rid="fig2-1352458511434370">Figure 2</xref>). An anti-neurofascin humoral response was detected in one-third of MS sera, with the highest titers in chronic MS compared to relapsing–remitting MS and controls. However, some non-MS samples (from controls and other inflammatory neurological diseases) were also positive.<sup><xref ref-type="bibr" rid="bibr7-1352458511434370">7</xref></sup> In contrast, although a serum antibody response directed against TAG1 was detected in MS sera, it was seen in the majority of donors, irrespective of the diagnostic (MS and other diseases of the central nervous system). Similarly, in cerebrospinal fluid, no difference for TAG1 humoral response was detected between MS samples and other non-inflammatory CNS diseases.<sup><xref ref-type="bibr" rid="bibr8-1352458511434370">8</xref></sup></p>
<fig id="fig2-1352458511434370" position="float">
<label>Figure 2.</label>
<caption><p>Identification of axoglial antigens in MS: scheme of the experimental approach (this figure is from Derfuss et al.,<sup><xref ref-type="bibr" rid="bibr31-1352458511434370">31</xref></sup> with kind permission of Springer Science + Busines Media).</p></caption>
<graphic xlink:href="10.1177_1352458511434370-fig2.tif"/></fig>
<p>Whereas <italic>in vivo</italic> transferred anti-neurofascin monoclonal antibodies did not induce tissue damage, an acute and reversible axonal injury was elicited when an inflammatory environment (with opening of the blood–brain barrier) was induced by co-transferring myelin oligodendrocyte glycoprotein (MOG) specific T cells. Additionally, binding of these <italic>in vivo</italic> transferred anti-neurofascin antibodies was restricted to the node of Ranvier (therefore to the Nfasc186 axonal isoform), whereas the Nfasc155 oligodendroglial isoform was not recognized. The pathogenic role of anti-neurofascin antibody was further analyzed on hippocampal slices, with induction of electrophysiological modifications on Schaeffer collateral-commissural fibers, illustrated by a reduction of the presynaptic fiber volley.</p>
<p>Concerning TAG1 immune response, anti-TAG1 transferred antibodies induced no tissue damage. However, passive transfer of CD4<sup>+</sup> T-cells specific for rat TAG1 induced a clinical EAE, with inflammatory lesions predominating in the gray matter of the cortex. When TAG1 specific T cells were co-transferred with demyelinating anti-MOG antibodies, extensive gray matter demyelination and axonal loss were observed.</p>
<p>Taken together, these data support the concept of an MS immune attack directed against antigens expressed at nodal and perinodal regions, mediated by T cells and/or antibodies, and only targeting and damaging the neuronal component despite antigenic expression on both glia and axons.</p>
<p>These recent results are important opening in MS pathophysiology, suggesting that target of the immune dysregulation might not be solely directed against myelin constituents, and that axonal damage might be a direct result of an immune attack against nodal and perinodal proteins. Further analysis on a large cohort of MS patients and controls is, however, crucially needed to clearly demonstrate that high titers of anti-neurofascin antibodies truly discriminate between MS and controls. Moreover, whether these immune responses are early effector mechanisms of tissue damage or relate to later immune dysregulation due to epitope spreading is an open question. In this context, despite the fact that the highest titers of anti-neurofascin antibodies were detected in chronic MS cases, rather favoring the hypothesis of a secondary immune response, it would be of major interest to screen TAG1 and neurofascin immune response very early during disease evolution, at the first MS event or in pediatric cases of MS.</p>
</sec>
<sec id="section5-1352458511434370">
<title>Nodal and perinodal proteins: new players in multiple sclerosis pathology?</title>
<p>These different studies have highlighted the potential role of nodal and perinodal proteins in MS pathophysiology. On the one hand, redistribution of nodal (sodium channels) proteins on the denuded axons might influence axonal function and survival depending on the molecular identities of the sodium channels expressed. On the other hand, these nodal and perinodal proteins may be the target of an immune response in MS, eliciting a direct, ‘demyelination independent’ axonal pathology. That an immune response directed against nodal antigens results into direct axonal damage is likely because the axonal surface is accessible at the node of Ranvier, which is not covered with myelin. This is what has been observed in the case of the transferred anti-neurofascin antibodies, showing a binding to the Nfasc186 isoform at the node of Ranvier. In contrast when the antigen is ‘hidden’ under the myelin sheath (such as Nfasc155 or TAG1), antibodies alone do not induce tissue damage, and additional mechanisms are needed for antigen exposure.</p>
<p>In addition to an acute and potentially reversible axonal pathology, this immune response directed against nodal and perinodal components might play a role in later phases of the tissue damage process. As nodal and perinodal proteins are diffusely expressed along the demyelinated axon, it might be speculated that an immune response directed against these components could exacerbate ‘demyelination dependent’ axonal pathology by reaching previously hidden antigens, which are now exposed and diffusely expressed along the denuded fiber. A deleterious role on non-myelinated (small caliber) axons which diffusely express these antigens is also possible. In addition, as neurofascin antibodies have been shown <italic>in vitro</italic> to prevent the myelination process by interacting with the Nfasc155/Caspr/contactin complex<sup><xref ref-type="bibr" rid="bibr30-1352458511434370">30</xref></sup> it is speculated that the persistence of such an axoglial immune response might hamper the remyelination process, by targeting oligodendroglial isoform of neurofascin. Finally, whether an immune response exists against other axonal molecules expressed at the node, paranode and juxta-paranode, as well as at the axonal initial segment, is unknown. Further analysis in MS and experimental models is needed to better understand what might be a major breakthrough in MS pathophysiology.</p>
</sec>
</body>
<back>
<ack><p>We thank Sean Freeman for careful reading of the manuscript, and Drs Linington and Meinl for kindly providing us with <xref ref-type="fig" rid="fig2-1352458511434370">Figure 2</xref>.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. AD is supported by a FRM post-doctoral fellowship.</p>
</fn>
<fn fn-type="conflict">
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511434370">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nikic</surname><given-names>I</given-names></name>
<name><surname>Merkler</surname><given-names>D</given-names></name>
<name><surname>Sorbara</surname><given-names>C</given-names></name>
<name><surname>Brinkoetter</surname><given-names>M</given-names></name>
<name><surname>Kreutzfeldt</surname><given-names>M</given-names></name>
<name><surname>Bareyre</surname><given-names>FM</given-names></name><etal/>
</person-group>. <article-title>A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis</article-title>. <source>Nat Med</source> <year>2011</year>; <volume>17</volume>: <fpage>495</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511434370">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lassmann</surname><given-names>H</given-names></name>
</person-group>. <article-title>Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models</article-title>. <source>Exp Neurol</source> <year>2010</year>; <volume>225</volume>: <fpage>2</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511434370">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhat</surname><given-names>R</given-names></name>
<name><surname>Steinman</surname><given-names>L</given-names></name>
</person-group>. <article-title>Innate and adaptive autoimmunity directed to the central nervous system</article-title>. <source>Neuron</source> <year>2009</year>; <volume>64</volume>: <fpage>123</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511434370">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Da</surname><given-names>RR</given-names></name>
<name><surname>Guo</surname><given-names>W</given-names></name>
<name><surname>Ren</surname><given-names>HM</given-names></name>
<name><surname>Hilgenberg</surname><given-names>LG</given-names></name>
<name><surname>Sobel</surname><given-names>RA</given-names></name><etal/>
</person-group>. <article-title>Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients with multiple sclerosis</article-title>. <source>J Clin Immunol</source> <year>2005</year>; <volume>25</volume>: <fpage>254</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511434370">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartos</surname><given-names>A</given-names></name>
<name><surname>Fialova</surname><given-names>L</given-names></name>
<name><surname>Soukupova</surname><given-names>J</given-names></name>
<name><surname>Kukal</surname><given-names>J</given-names></name>
<name><surname>Malbohan</surname><given-names>I</given-names></name>
<name><surname>Pit’ha</surname><given-names>J</given-names></name>
</person-group>. <article-title>Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis</article-title>. <source>J Neurol</source> <year>2007</year>; <volume>254</volume>: <fpage>20</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511434370">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krishnamoorthy</surname><given-names>G</given-names></name>
<name><surname>Saxena</surname><given-names>A</given-names></name>
<name><surname>Mars</surname><given-names>LT</given-names></name>
<name><surname>Domingues</surname><given-names>HS</given-names></name>
<name><surname>Mentele</surname><given-names>R</given-names></name>
<name><surname>Ben-Nun</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis</article-title>. <source>Nat Med</source> <year>2009</year>; <volume>15</volume>: <fpage>626</fpage>–<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511434370">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathey</surname><given-names>EK</given-names></name>
<name><surname>Derfuss</surname><given-names>T</given-names></name>
<name><surname>Storch</surname><given-names>MK</given-names></name>
<name><surname>Williams</surname><given-names>KR</given-names></name>
<name><surname>Hales</surname><given-names>K</given-names></name>
<name><surname>Woolley</surname><given-names>DR</given-names></name><etal/>
</person-group>. <article-title>Neurofascin as a novel target for autoantibody-mediated axonal injury</article-title>. <source>J Exp Med</source> <year>2007</year>; <volume>204</volume>: <fpage>2363</fpage>–<lpage>2372</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511434370">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Derfuss</surname><given-names>T</given-names></name>
<name><surname>Parikh</surname><given-names>K</given-names></name>
<name><surname>Velhin</surname><given-names>S</given-names></name>
<name><surname>Braun</surname><given-names>M</given-names></name>
<name><surname>Mathey</surname><given-names>E</given-names></name>
<name><surname>Krumbholz</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2009</year>; <volume>106</volume>: <fpage>8302</fpage>–<lpage>8307</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511434370">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waxman</surname><given-names>SG</given-names></name>
<name><surname>Ritchie</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Molecular dissection of the myelinated axon</article-title>. <source>Ann Neurol</source> <year>1993</year>; <volume>33</volume>: <fpage>121</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511434370">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname><given-names>FH</given-names></name>
<name><surname>Catterall</surname><given-names>WA</given-names></name>
</person-group>. <article-title>Overview of the voltage-gated sodium channel family</article-title>. <source>Genome Biol</source> <year>2003</year>; <volume>4</volume>: <fpage>207</fpage>.</citation>
</ref>
<ref id="bibr11-1352458511434370">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salzer</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Polarized domains of myelinated axons</article-title>. <source>Neuron</source> <year>2003</year>; <volume>40</volume>: <fpage>297</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511434370">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poliak</surname><given-names>S</given-names></name>
<name><surname>Peles</surname><given-names>E</given-names></name>
</person-group>. <article-title>The local differentiation of myelinated axons at nodes of Ranvier</article-title>. <source>Nat Rev Neurosci</source> <year>2003</year>; <volume>4</volume>: <fpage>968</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511434370">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leterrier</surname><given-names>C</given-names></name>
<name><surname>Brachet</surname><given-names>A</given-names></name>
<name><surname>Dargent</surname><given-names>B</given-names></name>
<name><surname>Vacher</surname><given-names>H</given-names></name>
</person-group>. <article-title>Determinants of voltage-gated sodium channel clustering in neurons</article-title>. <source>Semin Cell Dev Biol</source> <year>2011</year>; <volume>22</volume>: <fpage>171</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr14-1352458511434370">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Susuki</surname><given-names>K</given-names></name>
<name><surname>Rasband</surname><given-names>MN</given-names></name>
</person-group>. <article-title>Molecular mechanisms of node of Ranvier formation</article-title>. <source>Curr Opin Cell Biol</source> <year>2008</year>; <volume>20</volume>: <fpage>616</fpage>–<lpage>623</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511434370">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Girault</surname><given-names>JA</given-names></name>
<name><surname>Peles</surname><given-names>E</given-names></name>
</person-group>. <article-title>Development of nodes of Ranvier</article-title>. <source>Curr Opin Neurobiol</source> <year>2002</year>; <volume>12</volume>: <fpage>476</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511434370">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sherman</surname><given-names>DL</given-names></name>
<name><surname>Brophy</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>Mechanisms of axon ensheathment and myelin growth</article-title>. <source>Nat Rev Neurosci</source> <year>2005</year>; <volume>6</volume>: <fpage>683</fpage>–<lpage>690</lpage>.</citation>
</ref>
<ref id="bibr17-1352458511434370">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rasband</surname><given-names>MN</given-names></name>
</person-group>. <article-title>Clustered K<sup>+</sup> channel complexes in axons</article-title>. <source>Neurosci Lett</source> <year>2010</year>; <volume>486</volume>: <fpage>101</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511434370">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Labasque</surname><given-names>M</given-names></name>
<name><surname>Faivre-Sarrailh</surname><given-names>C</given-names></name>
</person-group>. <article-title>GPI-anchored proteins at the node of Ranvier</article-title>. <source>FEBS Lett</source> <year>2010</year>; <volume>584</volume>: <fpage>1787</fpage>–<lpage>1792</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511434370">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rasband</surname><given-names>MN</given-names></name>
</person-group>. <article-title>Composition, assembly, and maintenance of excitable membrane domains in myelinated axons</article-title>. <source>Semin Cell Dev Biol</source> <year>2011</year>; <volume>22</volume>: <fpage>178</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr20-1352458511434370">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griffiths</surname><given-names>I</given-names></name>
<name><surname>Klugmann</surname><given-names>M</given-names></name>
<name><surname>Anderson</surname><given-names>T</given-names></name>
<name><surname>Yool</surname><given-names>D</given-names></name>
<name><surname>Thomson</surname><given-names>C</given-names></name>
<name><surname>Schwab</surname><given-names>MH</given-names></name><etal/>
</person-group>. <article-title>Axonal swellings and degeneration in mice lacking the major proteolipid of myelin</article-title>. <source>Science</source> <year>1998</year>; <volume>280</volume>: <fpage>1610</fpage>–<lpage>1613</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511434370">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dupree</surname><given-names>JL</given-names></name>
<name><surname>Coetzee</surname><given-names>T</given-names></name>
<name><surname>Blight</surname><given-names>A</given-names></name>
<name><surname>Suzuki</surname><given-names>K</given-names></name>
<name><surname>Popko</surname><given-names>B</given-names></name>
</person-group>. <article-title>Myelin galactolipids are essential for proper node of Ranvier formation in the CNS</article-title>. <source>J Neurosci</source> <year>1998</year>; <volume>18</volume>: <fpage>1642</fpage>–<lpage>1649</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511434370">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boiko</surname><given-names>T</given-names></name>
<name><surname>Rasband</surname><given-names>MN</given-names></name>
<name><surname>Levinson</surname><given-names>SR</given-names></name>
<name><surname>Caldwell</surname><given-names>JH</given-names></name>
<name><surname>Mandel</surname><given-names>G</given-names></name>
<name><surname>Trimmer</surname><given-names>JS</given-names></name><etal/>
</person-group>. <article-title>Compact myelin dictates the differential targeting of two sodium channel isoforms in the same axon</article-title>. <source>Neuron</source> <year>2001</year>; <volume>30</volume>: <fpage>91</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr23-1352458511434370">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arroyo</surname><given-names>EJ</given-names></name>
<name><surname>Xu</surname><given-names>T</given-names></name>
<name><surname>Grinspan</surname><given-names>J</given-names></name>
<name><surname>Lambert</surname><given-names>S</given-names></name>
<name><surname>Levinson</surname><given-names>SR</given-names></name>
<name><surname>Brophy</surname><given-names>PJ</given-names></name><etal/>
</person-group>. <article-title>Genetic dysmyelination alters the molecular architecture of the nodal region</article-title>. <source>J Neurosci</source> <year>2002</year>; <volume>22</volume>: <fpage>1726</fpage>–<lpage>1737</lpage>.</citation>
</ref>
<ref id="bibr24-1352458511434370">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lappe-Siefke</surname><given-names>C</given-names></name>
<name><surname>Goebbels</surname><given-names>S</given-names></name>
<name><surname>Gravel</surname><given-names>M</given-names></name>
<name><surname>Nicksch</surname><given-names>E</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Braun</surname><given-names>PE</given-names></name><etal/>
</person-group>. <article-title>Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination</article-title>. <source>Nat Genet</source> <year>2003</year>; <volume>33</volume>: <fpage>366</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr25-1352458511434370">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Craner</surname><given-names>MJ</given-names></name>
<name><surname>Newcombe</surname><given-names>J</given-names></name>
<name><surname>Black</surname><given-names>JA</given-names></name>
<name><surname>Hartle</surname><given-names>C</given-names></name>
<name><surname>Cuzner</surname><given-names>ML</given-names></name>
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na<sup>+</sup>/Ca<sup>2+</sup> exchanger</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2004</year>; <volume>101</volume>: <fpage>8168</fpage>–<lpage>8173</lpage>.</citation>
</ref>
<ref id="bibr26-1352458511434370">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coman</surname><given-names>I</given-names></name>
<name><surname>Aigrot</surname><given-names>MS</given-names></name>
<name><surname>Seilhean</surname><given-names>D</given-names></name>
<name><surname>Reynolds</surname><given-names>R</given-names></name>
<name><surname>Girault</surname><given-names>JA</given-names></name>
<name><surname>Zalc</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis</article-title>. <source>Brain</source> <year>2006</year>; <volume>129</volume>: <fpage>3186</fpage>–<lpage>3195</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511434370">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howell</surname><given-names>O</given-names></name>
<name><surname>Palser</surname><given-names>A</given-names></name>
<name><surname>Polito</surname><given-names>A</given-names></name>
<name><surname>Melrose</surname><given-names>S</given-names></name>
<name><surname>Zonta</surname><given-names>B</given-names></name>
<name><surname>Scheiermann</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis</article-title>. <source>Brain</source> <year>2006</year>; <volume>129</volume>: <fpage>3173</fpage>–<lpage>3185</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511434370">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolswijk</surname><given-names>G</given-names></name>
<name><surname>Balesar</surname><given-names>R</given-names></name>
</person-group>. <article-title>Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis</article-title>. <source>Brain</source> <year>2003</year>; <volume>126</volume>: <fpage>1638</fpage>–<lpage>1649</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511434370">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howell</surname><given-names>OW</given-names></name>
<name><surname>Rundle</surname><given-names>JL</given-names></name>
<name><surname>Garg</surname><given-names>A</given-names></name>
<name><surname>Komada</surname><given-names>M</given-names></name>
<name><surname>Brophy</surname><given-names>PJ</given-names></name>
<name><surname>Reynolds</surname><given-names>R</given-names></name>
</person-group>. <article-title>Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis</article-title>. <source>J Neuropath Exp Neurol</source> <year>2010</year>; <volume>69</volume>: <fpage>1017</fpage>–<lpage>1033</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511434370">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charles</surname><given-names>P</given-names></name>
<name><surname>Tait</surname><given-names>S</given-names></name>
<name><surname>Faivre-Sarrailh</surname><given-names>C</given-names></name>
<name><surname>Barbin</surname><given-names>G</given-names></name>
<name><surname>Gunn-Moore</surname><given-names>F</given-names></name>
<name><surname>Denisenko-Nehrbass</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Neurofascin is a glial receptor for the paranodin/Caspr–contactin axonal complex at the axoglial junction</article-title>. <source>Curr Biol</source> <year>2002</year>; <volume>12</volume>: <fpage>217</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr31-1352458511434370">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Derfuss</surname><given-names>T</given-names></name>
<name><surname>Linington</surname><given-names>C</given-names></name>
<name><surname>Hohlfeld</surname><given-names>R</given-names></name>
<name><surname>Meinl</surname><given-names>E</given-names></name>
</person-group>. <article-title>Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury</article-title>. <source>J Mol Med</source> <year>2010</year>; <volume>88</volume>: <fpage>753</fpage>–<lpage>761</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>